Operative Korrektur der Beinachse bei X-chromosomaler Hypophosphatämie

Zusammenfassung

Die X-chromosomale Hypophosphatämie (XLH, OMIM 307800) ist eine seltene Knochenerkrankung, die durch Mutationen in PHEX (PHEX phosphate regulating endopeptidase X-linked) verursacht wird. Rachitis, Osteomalazie, Kleinwuchs und komplexe Beindeformitäten gehören zu den wichtigsten skelettalen Veränderungen dieser Erkrankung. Die konservative Therapie mit Phosphatsalzen oder FGF23-hemmenden Antikörpern kann Beschwerden nachweislich verbessern. Dennoch zeigen rezente Studien eindrücklich das Ausmaß der Krankheitstypischen Gangveränderungen, Beindeformitäten und damit einhergehenden Verminderung der Lebensqualität. Ein bedeutendes orthopädisches Behandlungsziel an der unteren Extremität ist der Erhalt bzw. die Herstellung physiologischer Beinachsenstellung. Dieser Artikel fasst die orthopädische Therapie von Beindeformitäten bei Kindern und Erwachsenen mit XLH in einem multidisziplinären Setting zusammen.

Abstract

X-linked hypophosphatemia (XLH, OMIM # 307800) is a rare disorder of bone metabolism caused by loss-of-function of phosphate-regulating gene with homology to endopeptidases on the X chromosome (PHEX). A dysregulation of the main regulator of fibroblast growth factor 23 (FGF23) leads to chronic renal phosphate loss and to associated skeletal changes: rickets, osteomalacia, short stature and complex leg deformities. Conservative therapies such as treatment with phosphate salts or FGF23-inhibiting antibodies can improve the symptoms. However, recent studies showed disease-specific gait deviations, lower limb deformities and high burden of disease of children and adults with XLH. Therefore, physiological lower limb alignment needs to be the main treatment focus for orthopedic surgeons. This article describes the orthopedic treatment of lower limb deformities in children and adults in a multidisciplinary treatment setting.

Schlüsselwörter

XLH - Phosphatdiabetes - Beindeformität - Wachstumslenkung

Key words

XLH - deformity - guided growth - deformity correction

Publikationsverlauf

Eingereicht: 26. August 2022

Angenommen: 10. Oktober 2022

Artikel online veröffentlicht:
15. Dezember 2022

• Literatur

• 1 Trombetti A, Al-Daghri N, Brandi ML. et al. Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia. Nat Rev Endocrinol 2022; 18: 366-384 DOI: 10.1038/s41574-022-00662-x.
• 2 Raimann A, Mindler GT, Kocijan R. et al. Multidisciplinary patient care in X-linked hypophosphatemic rickets: one challenge, many perspectives. Wien Med Wochenschr 2020; 170: 116-123 DOI: 10.1007/s10354-019-00732-2.
• 3 Mindler GT, Kranzl A, Stauffer A. et al. Disease-specific gait deviations in pediatric patients with X-linked hypophosphatemia. Gait Posture 2020; 81: 78-84 DOI: 10.1016/j.gaitpost.2020.07.007.
• 4 Mindler GT, Stauffer A, Kranzl A. et al. Persistent Lower Limb Deformities Despite Amelioration of Rickets in X-Linked Hypophosphatemia (XLH) – A Prospective Observational Study. Front Endocrinol 2022; 13: 866170 DOI: 10.3389/fendo.2022.866170.
• 5 Mindler GT, Kranzl A, Stauffer A. et al. Lower Limb Deformity and Gait Deviations Among Adolescents and Adults With X-Linked Hypophosphatemia. Front Endocrinol 2021; 12: 754084 DOI: 10.3389/fendo.2021.754084.
• 6 Steele A, Gonzalez R, Garbalosa JC. et al. Osteoarthritis, Osteophytes, and Enthesophytes Affect Biomechanical Function in Adults With X-linked Hypophosphatemia. J Clin Endocrinol Metab 2020; 105: e1798-e1814 DOI: 10.1210/clinem/dgaa064.
• 7 Seefried L, Smyth M, Keen R. et al. Burden of disease associated with X-linked hypophosphataemia in adults: a systematic literature review. Osteoporos Int 2021; 32: 7-22 DOI: 10.1007/s00198-020-05548-0.
• 8 Scorcelletti M, Kara S, Zange J. et al. Lower limb bone geometry in adult individuals with X-linked hypophosphatemia: an observational study. Osteoporos Int 2022; 33: 1601-1611 DOI: 10.1007/s00198-022-06385-z.
• 9 Raimann A, Stauffer A, Penzkofer S. et al. Characterization of lower limb deformities in children and adolescents with XLH. Bone Rep 2022; 16: 101505
• 10 Bonnet-Lebrun A, Linglart A, De Tienda M. et al. Quantitative analysis of lower limb and pelvic deformities in children with X-linked hypophosphatemic rickets. Orthop Traumatol Surg Res. 2021; 103187 DOI: 10.1016/j.otsr.2021.103187.
• 11 Genest F, Boehle F, Wander C. et al. Muskoloskelettale und funktionelle Einschränkugnen bei erwachsenen Patienten mit X-chromosomaler Hyophosphatämie (XLH). Osteologie 2020; 29: 54
• 12 Veilleux LN, Cheung M, Ben Amor M. et al. Abnormalities in Muscle Density and Muscle Function in Hypophosphatemic Rickets. J Clin Endocrinol Metab 2012; 97: E1492-E1498 DOI: 10.1210/jc.2012-1336.
• 13 Imel EA, Glorieux FH, Whyte MP. et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. The Lancet 2019; 393: 2416-2427 DOI: 10.1016/S0140-6736(19)30654-3.
• 14 Insogna KL, Briot K, Imel EA. et al. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis: Efficacy of Burosumab in Adults with XLH. J Bone Miner Res 2018; 33: 1383-1393 DOI: 10.1002/jbmr.3475.
• 15 Portale AA, Carpenter TO, Brandi ML. et al. Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period. Calcif Tissue Int 2019; 105: 271-284 DOI: 10.1007/s00223-019-00568-3.
• 16 Brandi ML, Jan de Beur S, Briot K. et al. Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study. Calcif Tissue Int 2022; 111: 409-418 DOI: 10.1007/s00223-022-01006-7.
• 17 Kanamalla K, Fuchs R, Herzog C. et al. An Evidence-based Physical Therapy Prescription for Adults With X-linked Hypophosphatemia. J Endocr Soc 2022; 6: bvac094 DOI: 10.1210/jendso/bvac094.
• 18 Rothenbuhler A, Fadel N, Debza Y. et al. High Incidence of Cranial Synostosis and Chiari I Malformation in Children With X-Linked Hypophosphatemic Rickets (XLHR. J Bone Miner Res 2019; 34: 490-496 DOI: 10.1002/jbmr.3614.
• 19 Zhukouskaya VV, Rothenbuhler A, Colao A. et al. Increased prevalence of overweight and obesity in children with X-linked hypophosphatemia. Endocr Connect 2020; 9: 144-153 DOI: 10.1530/EC-19-0481.
• 20 Bloudeau L, Linglart A, Flammier S. et al. X-linked hypophosphatemia, obesity and arterial hypertension: data from the XLH21 study. Pediatr Nephrol. 2022 [im Druck]